Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. Impel Pharmaceuticals Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.

Impel Pharmaceuticals Inc.

Impel Pharmaceuticals is focused on developing and providing transformative therapies for people suffering from diseases with high unmet needs across various disease areas in addition to the central nervous system (CNS), through the pioneering of an optimized approach to drug delivery. We offer and develop treatments that pair the Company’s proprietary Precision Olfactory Delivery (POD®) technology with well-established therapeutics. 

Impel Pharmaceuticals

Summer is a tough time of year for #migraine and #headaches. To best celebrate #freedom with your friends and family, be mindful of your triggers and keep your acute meds on hand.
 
Wishing everyone a safe and happy #IndependenceDay!

Trudhesa® (DHE mesylate) delivers a trusted #migraine therapeutic to the vascular-rich upper nasal space via the POD® device developed by our co-founder, CTO & CDO, John Hoekman. This results in IV-like efficacy at home - not via injection in an ER.

The Impel team proudly supports the #migraine community. Today we're wearing our #ShadesForMigraine to raise awareness about this complex, neurological disease that's more than just a #headache. 

#MHAM #MigraineAwareness

A second poster on preliminary real-world data underscores the need for non-oral treatment options for #migraine given the prevalence of pre-existing #gastrointestinal disorders among those prescribed with Trudhesa® (DHE mesylate).

See abstract P-160 in Headache: https://lnkd.in/eV8n_mNw

Read our press release to learn more: https://lnkd.in/eEkwReSh

#MHAM Dr. Sheena Aurora

Preliminary real-world data at #AHSAM suggest that concomitant preventive & acute medication use generally decreases in patients taking Trudhesa® (DHE mesylate) nasal spray, and that use of antinausea medications (common with DHE administered via IV) did not increase.

See abstract P-161 in Headache: https://lnkd.in/eV8n_mNw

Read yesterday's press release to learn more: https://lnkd.in/eEkwReSh 

#Migraine #MHAM Zubair Ahmed

	Dec '19	Dec '20	Dec '21	Dec '22
account payables	2.73M -	4.31M 58.31%	6.37M 47.59%	6.09M 4.32%
accumulated other comprehensive income loss			-97.91M -
cash and cash equivalents	37.00M -	7.09M 80.82%	88.21M 1,143.30%	60.65M 31.24%
cash and short term investments	37.00M -	7.09M 80.82%	88.21M 1,143.30%	60.65M 31.24%
common stock			23K -	24K 4.35%
deferred revenue		3.17M -
deferred revenue non current
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory			2.82M -	8.43M 198.41%
long term debt		7.99M -	29.45M 268.40%	49.65M 68.57%
long term investments
net debt	-37.00M -	1.32M 103.56%	-58.76M 4,565.20%	-9.47M 83.89%
net receivables	201K -	229K 13.93%	1.35M 490.39%	7.44M 450.59%
other assets
other current assets			2.19M -	3.28M 50.09%
other current liabilities	5.60M -	2.62M 53.15%	9.59M 265.64%	14.53M 51.56%
other liabilities
other non current assets		187K -	187K 0%	1.75M 833.69%
other non current liabilities		127.04M -		60.90M -
othertotal stockholders equity	760K -	4.76M 526.58%	267.28M 5,512.83%	276.93M 3.61%
preferred stock			97.91M -
property plant equipment net	2.74M -	3.70M 35.04%	3.15M 14.89%	7.00M 122.13%
retained earnings	-92.46M -	-138.26M 49.53%	-214.80M 55.36%	-321.11M 49.49%
short term debt		417K -		1.54M -
short term investments
tax assets
tax payables
total assets	42.27M -	12.06M 71.47%	97.91M 711.94%	88.55M 9.56%
total current assets	39.52M -	8.17M 79.32%	94.58M 1,057.32%	79.81M 15.61%
total current liabilities	8.32M -	10.53M 26.48%	15.95M 51.57%	22.16M 38.92%
total debt		8.41M -	29.45M 250.14%	51.19M 73.81%
total investments
total liabilities	133.97M -	145.56M 8.65%	45.40M 68.81%	132.71M 192.28%
total liabilities and stockholders equity	42.27M -	12.06M 71.47%	97.91M 711.94%	88.55M 9.56%
total non current assets	2.74M -	3.89M 41.86%	3.34M 14.18%	8.74M 162.02%
total non current liabilities	125.65M -	135.03M 7.47%	29.45M 78.19%	110.54M 275.36%
total stockholders equity	-91.70M -	-133.50M 45.58%	52.51M 139.33%	-44.16M 184.10%

COM:IMPELPHARMA

Impel Pharmaceuticals Inc.

Last Close

0.06

20/12 20:58

Market Cap

956K

Beta: -

Volume Today

720.03K

Avg: -

Preview